US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Cyclacel Pharmaceuticals, Inc. - Common Stock (NQ:CYCC)

6.365 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cyclacel Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership
From Cyclacel
Via GlobeNewswire
News headline image
These stocks are moving in today's after hours session ↗
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Nasdaq Surges Over 1%; Cerence Shares Spike Higher ↗
 
Via Benzinga
News headline image
Why Cyclacel Pharmaceuticals (CYCC) Stock Is Skyrocketing ↗
Cyclacel Pharmaceuticals shares are trading higher by 77% during Friday's session. The company announced a securities purchase agreement with investor David Lazar. 
Via Benzinga
News headline image
Dow Jumps Over 100 Points; ISM Manufacturing PMI Increases In December ↗
 
Via Benzinga
Topics Stocks
News headline image
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO 
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
From Cyclacel
Via GlobeNewswire
News headline image
Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
From Cyclacel
Via GlobeNewswire
News headline image
Why Rocket Lab Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
From Cyclacel
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
- Interim data for fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities - 
From Cyclacel
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities 
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
From Cyclacel
Via GlobeNewswire
News headline image
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
From Cyclacel
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >